Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-3467 with or without olaparib in advanced solid tumors
NCT06560632Phase 1Terminated
- Sponsor
- Repare Therapeutics
- Start
- Sep 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RP-3467 in ovarian cancer, breast cancer, prostate cancer (PCa) and 1 more (2 arms), sponsored by Repare Therapeutics. Primary endpoint: Dose-limiting Toxicities. Started Sep 2024; status: terminated.
02
Drugs
RP-3467
03
Conditions
ovarian cancerbreast cancerprostate cancer (PCa)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06560632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560632.